Nectar Lifesciences Ltd.

₹10.52

-0.2 (-2.2%)

NECLIFE Share Price

Pharmaceuticals & Biotechnology

As on August 19, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 205 Cr

P/E Ratio-2.08

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	10.97	Bearish
10-DMA	10.77	Bearish
20-DMA	10.59	Bearish
50-DMA	11.06	Bearish
100-DMA	11.5	Bearish
200-DMA	13.48	Bearish

Historical Performance

1 Year

-30.1%

3 Years

-56.3%

5 Years

-66.1%

10 Years

-70.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	16,700	16,841	15,237	16,688	15,433
Total Expenditure	16,995	15,325	14,707	15,103	14,418
Other Income	75	171	531	113	114
Operating Profit	-221	1,686	1,061	1,699	1,128
Interest	771	896	894	788	1,120
Depreciation	624	607	591	570	603
Profit Before Tax	-1,615	183	-424	341	-848
Consolidated Net Profit	-1,137	50	-242	250	-733
Adjusted EPS	-5	---	-1	1	-3

Compounded Sales Growth

10 Years:0.3

5 Years:-6.7

3 Years:0

TTM:-0.2

Compounded Profit Growth

10 Years:-9.9

5 Years:4

3 Years:9.5

TTM:51.1

Stock Price CAGR

10 Years:-11.4

5 Years:-18.4

3 Years:-24.1

TTM:-30.3

Return on Equity

10 Years:2.4

5 Years:-3.3

3 Years:-1.1

last year:-5.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	224	224	224	224	224
Total Reserves	9,337	10,468	10,422	10,655	10,396
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	145	1,415	2,131	2,963	1,264
Other Current Liabilities	1,403	1,387	1,114	1,227	1,316
Short Term Borrowings	4,402	4,122	4,589	5,028	7,120
Total Liabilities	19,922	21,836	21,686	23,880	23,758
Capital Work in Progress	567	658	778	851	986
Long Term Loans & Advances	134	126	109	123	147
Currents Investments	5	5	3	5	5
Short Term Loans and Advances	1,362	1,329	1,605	1,581	1,984
Total Current Assets	12,376	12,838	12,312	13,548	12,388
Total Assets	19,922	21,836	21,686	23,880	23,758
Adjusted Book Value	43	48	47	49	47

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -2.08, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -24.7%, indicating poor shareholder returns.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported a negative or negligible EBITDA of ₹-221 million, indicating weak operating profitability.
In the previous financial year, the company generated revenue of ₹16700 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 697612.7

No. of Shares: 66313 (Approx)

Performance:-30.2%

-302387.3

NIFTY Performance: -3.9%

1 day Top Gainers